Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863862 | 0.76 | HCRTR2 (0.41) | GFERHPGD | |
| SCHEMBL24630407 | 0.76 | COPS5 (0.43) | GFERNPC1LMNATP53MAPT | |
| SCHEMBL12659982 | 0.72 | PTGS1 (0.32) | NPC1LMNATP53MAPTHPGD | |
| SCHEMBL10110823 | 0.69 | GFER (0.49) | GFERPIK3CGNPC1LMNATP53 | |
| SCHEMBL26546527 | 0.68 | CDK2 (0.38) | LMNATP53MAPTCDK5CDK5R1 | |
| SCHEMBL23682669 | 0.67 | GFER (0.36) | GFERNPC1LMNAMAPTRAB9A | |
| SCHEMBL19633043 | 0.66 | PIK3CG (0.46) | GFERPIK3CGNPC1MAPTRAB9A | |
| SCHEMBL25697722 | 0.64 | GFER (0.33) | GFER | |
| SCHEMBL23815725 | 0.64 | SHMT2 (0.39) | NPC1MAPTRAB9ACDK5CDK5R1 | |
| SCHEMBL2880579 | 0.64 | COPS5 (0.35) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-7700765-B2 | DNA minor groove binding compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20070117760-A1 | Dna minor groove binding compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | GFER 3523/4885PIK3CG 4463/4885NPC1 3709/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | GFER 1634/4885PIK3CG 4481/4885NPC1 3083/4885 |
| US-20070117760-A1 | Dna minor groove binding compounds | PCNA, POLL, POLM | GFER 4531/4885PIK3CG 3561/4885NPC1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.